Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) - Investment analysts at HC Wainwright raised their Q3 2025 earnings estimates for Protara Therapeutics in a note issued to investors on Monday, August 11th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($0.38) per share for the quarter, up from their prior forecast of ($0.54). HC Wainwright has a "Buy" rating and a $23.00 price objective on the stock. The consensus estimate for Protara Therapeutics' current full-year earnings is ($3.32) per share. HC Wainwright also issued estimates for Protara Therapeutics' Q4 2025 earnings at ($0.40) EPS, FY2026 earnings at ($1.96) EPS, FY2027 earnings at ($1.98) EPS, FY2028 earnings at ($1.31) EPS and FY2029 earnings at ($0.60) EPS.
Protara Therapeutics (NASDAQ:TARA - Get Free Report) last released its quarterly earnings results on Monday, August 11th. The company reported ($0.35) EPS for the quarter, beating analysts' consensus estimates of ($0.43) by $0.08.
Separately, Jones Trading raised shares of Protara Therapeutics to a "strong-buy" rating and set a $21.00 target price for the company in a research note on Thursday, May 22nd. One research analyst has rated the stock with a Strong Buy rating and five have given a Buy rating to the company. According to data from MarketBeat.com, Protara Therapeutics currently has an average rating of "Buy" and an average price target of $19.60.
Check Out Our Latest Analysis on TARA
Protara Therapeutics Stock Down 4.7%
Shares of Protara Therapeutics stock traded down $0.15 during trading on Thursday, reaching $3.07. 61,253 shares of the company were exchanged, compared to its average volume of 329,991. Protara Therapeutics has a twelve month low of $1.60 and a twelve month high of $10.48. The firm has a market capitalization of $118.44 million, a price-to-earnings ratio of -1.90 and a beta of 1.42. The business has a 50-day moving average price of $3.11 and a 200-day moving average price of $3.58.
Institutional Investors Weigh In On Protara Therapeutics
A number of large investors have recently bought and sold shares of the company. Bridgeway Capital Management LLC grew its stake in Protara Therapeutics by 49.6% during the second quarter. Bridgeway Capital Management LLC now owns 59,830 shares of the company's stock worth $181,000 after buying an additional 19,830 shares in the last quarter. Acorn Capital Advisors LLC boosted its position in Protara Therapeutics by 36.9% during the 2nd quarter. Acorn Capital Advisors LLC now owns 1,752,115 shares of the company's stock worth $5,309,000 after buying an additional 472,315 shares during the period. Adage Capital Partners GP L.L.C. bought a new position in Protara Therapeutics during the 2nd quarter worth approximately $1,212,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in Protara Therapeutics during the 2nd quarter worth approximately $53,000. Finally, Velan Capital Investment Management LP raised its holdings in Protara Therapeutics by 28.3% during the 2nd quarter. Velan Capital Investment Management LP now owns 2,139,000 shares of the company's stock worth $6,481,000 after purchasing an additional 471,200 shares during the last quarter. 38.13% of the stock is currently owned by institutional investors and hedge funds.
Protara Therapeutics Company Profile
(
Get Free Report)
Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
Featured Articles
Before you consider Protara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protara Therapeutics wasn't on the list.
While Protara Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access